Advertisement

Pathology of Bone Metastasis

  • Carlo Della Rocca
  • Claudio Di Cristofano
Chapter

Abstract

Bone metastases are a frequent complication of advanced cancer. Interactions between cancer cells and marrow stromal cells and bone turnover mechanisms are crucial in metastases growth and the pathogenesis of bone damage. Metastatic tumour cells stimulate the bone remodelling and indirectly induce the osteocytes to release several growth factors that promote the proliferation of stromal, haematopoietic and neoplastic cells in a sort of vicious circle. Histological examination of bone metastasis of known origin is performed usually to define prognostic and/or predictive markers for target cancer therapy; in the 10–30% of patients in which the primary tumour is not identified, the histologic findings derived from bone biopsy could be diagnostic by morphological or immunohistochemical assessment of the neoplastic tissue.

Notes

Acknowledgements

The authors are grateful to Dr. Martina Leopizzi for helping in building iconography and to Dr. Carmen Mazzitelli and Dr. Caterina Chiappetta for the critical review of the manuscript.

References

  1. 1.
    Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28:5132–9.CrossRefPubMedGoogle Scholar
  2. 2.
    Fizazi K, Lipton A, Mariette X, Body JJ, Rahim Y, Gralow JR, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol. 2009;27:1564–71.CrossRefPubMedGoogle Scholar
  3. 3.
    Ulrich U, Rhiem K, Schmolling J, Flaskamp C, Paffenholz I, Salzer H, et al. Cross-linked type I collagen C- and N-telopeptides in women with bone metastases from breast cancer. Arch Gynecol Obstet. 2001;264:186–90.CrossRefPubMedGoogle Scholar
  4. 4.
    Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst. 2005;97:59–69.CrossRefPubMedGoogle Scholar
  5. 5.
    Coleman R, Body JJ, Aapro M, Hadji P, Herrstedt J. Bone health in cancer patients: ESMO clinical practice guidelines. Ann Oncol. 2014;25(Suppl 3):iii124–37.CrossRefPubMedGoogle Scholar
  6. 6.
    Van Poznak CH, Temin S, Yee GC, Janjan NA, Barlow WE, Biermann JS, et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol. 2011;29:1221–7.CrossRefPubMedGoogle Scholar
  7. 7.
    Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fossa SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–23.CrossRefPubMedGoogle Scholar
  8. 8.
    Martin RB. Does osteocyte formation cause the nonlinear refilling of osteons? Bone. 2000;26:71–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Robling AG, et al. Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem. 2008;283:5866–75.CrossRefGoogle Scholar
  10. 10.
    Tu X, et al. Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading. Bone. 2012;50:209–17.CrossRefPubMedGoogle Scholar
  11. 11.
    Leupin O, et al. Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function. J Biol Chem. 2011;286:19489–500.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Bellido T, Plotkin LI, Bruzzaniti A. Bone cells. In: Burr D, Allen M, editors. Basic and applied bone biology. Atlanta: Elsevier; 2014. p. 27–45.CrossRefGoogle Scholar
  13. 13.
    Teitelbaum SL. Bone resorption by osteoclasts. Science. 2000;289:1504–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology. 2001;142:5050–5.CrossRefPubMedGoogle Scholar
  15. 15.
    Dallas SL, Prideaux M, Bonewald LF. The osteocyte: an endocrine cell and more. Endocr Rev. 2013;34:658–90.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Bonewald LF. The amazing osteocyte. J Bone Miner Res. 2011;26:229–38.CrossRefPubMedGoogle Scholar
  17. 17.
    Xiong J, et al. Matrix-embedded cells control osteoclast formation. Nat Med. 2011;17:1235–41.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Nakashima T, et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med. 2011;17:1231–4.CrossRefPubMedGoogle Scholar
  19. 19.
    Suva LJ. Sclerostin and the unloading of bone. J Bone Miner Res. 2009;24:1649–50.CrossRefPubMedGoogle Scholar
  20. 20.
    Wijenayaka AR, et al. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS One. 2011;6:e25900.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Compton JT, Lee FY. A review of osteocyte function and the emerging importance of sclerostin. J Bone Joint Surg Am. 2014;96:1659–68.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Zhou JZ, et al. Differential impact of adenosine nucleotides released by osteocytes on breast cancer growth and bone metastasis. Oncogene. 2015;34:1831–42.CrossRefPubMedGoogle Scholar
  23. 23.
    Vandecandelaere M, Flipo RM, Cortet B, Catanzariti L, Duquesnoy B, Delcambre B. Bone metastases revealing primary tumors. Comparison of two series separated by 30 years. Joint Bone Spine. 2004;71(3):224–9.CrossRefPubMedGoogle Scholar
  24. 24.
    Nottebaert M, Exner GU, von Hochstetter AR, Schreiber A. Metastatic bone disease from occult carcinoma: a profile. Int Orthop. 1989;13(2):119–23.CrossRefPubMedGoogle Scholar
  25. 25.
    Cooke KS, Kirpekar M, Abiri MM, Shreefter C. US case of the day. Skeletal metastasis from poorly differentiated carcinoma of unknown origin. Radiographics. 1997;17(2):542–4.CrossRefPubMedGoogle Scholar
  26. 26.
    Piccioli A. Breast cancer bone metastases: an orthopedic emergency. J Orthop Traumatol. 2014;15(2):143–4.CrossRefPubMedGoogle Scholar
  27. 27.
    Katagiri H, Takahashi M, Inagaki J, Sugiura H, Ito S, Iwata H. Determining the site of the primary cancer in patients with skeletal metastasis of unknown origin: a retrospective study. Cancer. 1999;86(3):533–7.CrossRefPubMedGoogle Scholar
  28. 28.
    Piccioli A, Capanna R. Il trattamento delle metastasi ossee. Linee Guida S.I.O.T; 2008.Google Scholar
  29. 29.
    Wedin R, Bauer HC, Skoog L, Söderlund V, Tani E. Cytological diagnosis of skeletal lesions. Fine-needle aspiration biopsy in 110 tumours. J Bone Joint Surg Br. 2000;82(5):673–8.CrossRefPubMedGoogle Scholar
  30. 30.
    Xu DL, Zhang XT, Wang GH, Li FB, Hu JY. Clinical features of pathologically confirmed metastatic bone tumors—a report of 390 cases. Ai Zheng. 2005;24(11):1404.PubMedGoogle Scholar
  31. 31.
    Conroy T, Platini C, Troufleau P, Dartois D, Lupors IE, Malissard L, et al. Presentation clinique et facteurspronostics au diagnostic de metastases osseuses. A propos de d’uneserie de 578 observations. Bull Cancer. 1993;80:S16e22.Google Scholar
  32. 32.
    Papagelopoulos P, Savvidou O, Galanis E, et al. Advances and challenges in diagnosis and management of skeletal metastases. Orthopedics. 2009;29(7):609–20.Google Scholar
  33. 33.
    Shih LY, Chen TH, Lo WH. Skeletal metastasis from occult carcinoma. J Surg Oncol. 1992;51(2):109–13.CrossRefPubMedGoogle Scholar
  34. 34.
    Airoldi G. Cancer of unknown primary origin: utility and futility in clinical practice. Ital J Med. 2012;6:315–26.CrossRefGoogle Scholar
  35. 35.
    Hemminki K, Riihimäki M, Sundquist K, Hemminki A. Site-specific survival rates for cancer of unknown primary according to location of metastases. Int J Cancer. 2013;133(1):182–9.CrossRefPubMedGoogle Scholar
  36. 36.
    Bitran JD, Ultmann JE. Malignancies of undetermined primary origin. Dis Mon. 1992;38(4):213–60.CrossRefPubMedGoogle Scholar
  37. 37.
    Oien KA, Dennis JL. Diagnostic work-up of carcinoma of unknown primary: from immunohistochemistry to molecular profiling. Ann Oncol. 2012;23(Suppl 10):271–7.CrossRefGoogle Scholar
  38. 38.
    Simon MA, Karluk MB. Skeletal metastases of unknown origin. Diagnostic strategy for orthopedic surgeons. Clin Orthop Relat Res. 1982;166:96–103.Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Medical-Surgical Sciences and BiotechnologiesSapienza University of Rome, Azienda Ospedaliera Universitaria Policlinico Umberto IRomeItaly
  2. 2.Pathology Unit, Department of Medical-Surgical Sciences and BiotechnologiesSapienza University of Rome - Polo PontinoLatinaItaly

Personalised recommendations